Document Detail


Oral administration of short-chain fatty acids reduces the intestinal mucositis caused by treatment with Ara-C in mice fed commercial or elemental diets.
MedLine Citation:
PMID:  9290130     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Swiss mice fed commercial or elemental diets and an oral short-chain fatty acid (SCFA) solution or saline were treated with the cytostatic drug Ara-C (cytarabine, 3.6 mg/mouse/day) for two or four days. Histopathological examination revealed less damage (atrophy, inflammation, or necrosis) to the small intestine and colon caused by Ara-C when SCFA was administered. Accordingly, protein and nucleotide concentrations in the intestinal mucosa were higher in the group receiving SCFA than in the group receiving a placebo of the same pH and osmolarity. Improvement by SCFA treatment was correlated with an increase in the height of the intestinal villi, with no alterations of the crypts. Furthermore, the number of intraepithelial lymphocytes was similar to normal values in animals receiving SCFA and Ara-C. When large doses of SCFA were administered, xanthomized enterocytes appeared, suggesting an accumulation of fatty acids in these cells. We conclude that oral administration of SCFA at close to physiological proportions reduces the inflammation and necrosis caused by Ara-C administration, thus representing a potential factor for the improvement of patients with mucositis caused by cancer treatment.
Authors:
M G Ramos; E A Bambirra; D C Cara; E C Vieira; J I Alvarez-Leite
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Nutrition and cancer     Volume:  28     ISSN:  0163-5581     ISO Abbreviation:  Nutr Cancer     Publication Date:  1997  
Date Detail:
Created Date:  1997-12-17     Completed Date:  1997-12-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7905040     Medline TA:  Nutr Cancer     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  212-7     Citation Subset:  IM    
Affiliation:
Departamento de Bioquímica e Immunologia, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Animals
Antimetabolites, Antineoplastic / administration & dosage,  toxicity*
Cohort Studies
Cytarabine / administration & dosage,  toxicity*
Diet
Fatty Acids, Volatile / administration & dosage,  therapeutic use*
Inflammation / chemically induced,  drug therapy,  pathology
Intestinal Diseases / chemically induced,  drug therapy*,  pathology
Intestinal Mucosa / drug effects,  pathology*
Intestine, Small / chemistry,  drug effects
Mice
Nucleotides / analysis
Chemical
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 0/Fatty Acids, Volatile; 0/Nucleotides; 147-94-4/Cytarabine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Vitamin B6 suppresses growth and expression of albumin gene in a human hepatoma cell line HepG2.
Next Document:  Prenatal theophylline and necrotizing enterocolitis in premature newborn infants.